EUVIMEDEUVIMED entdecken
Open Access

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma

Mekenzie M Peshoff, Pravesh Gupta, Shivangi Oberai, Rakesh Trivedi, Hiroshi Katayama, Prashanth Chakrapani, Minghao Dang, Simona Migliozzi, Joy Gumin, Divya B Kadri, Jessica K Lin, Nancy K Milam und 9 weitere

Neuro-Oncology · 03.05.2024 · 26 (5) · 826-839

DOI: 10.1093/neuonc/noad257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 18.01.2024. Verfasst von Mekenzie M Peshoff und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, Neurosurgery at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Glioblastoma, Membrane Glycoproteins, Phagocytosis. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, The University of Texas (UT) MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastomas (GBMs) are central nervous system tumors that resist standard-of-care interventions and even immune checkpoint blockade. Myeloid cells in the tumor microenvironment can contribute to GBM progression; therefore, emerging immunotherapeutic approaches include reprogramming these cells to achieve desirable antitumor activity. Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid signaling regulator that has been implicated in a variety of cancers and neurological diseases with contrasting functions, but its role in GBM immunopathology and progression is still under investigation.

Methods

Our reverse translational investigations leveraged single-cell RNA sequencing and cytometry of human gliomas to characterize TREM2 expression across myeloid subpopulations. Using 2 distinct murine glioma models, we examined the role of Trem2 on tumor progression and immune modulation of myeloid cells. Furthermore, we designed a method of tracking phagocytosis of glioma cells in vivo and employed in vitro assays to mechanistically understand the influence of TREM2 signaling on tumor uptake.

Results

We discovered that TREM2 expression does not correlate with immunosuppressive pathways, but rather showed strong a positive association with the canonical phagocytosis markers lysozyme (LYZ) and macrophage scavenger receptor (CD163) in gliomas. While Trem2 deficiency was found to be dispensable for gliomagenesis, Trem2+ myeloid cells display enhanced tumor uptake compared to Trem2- cells. Mechanistically, we demonstrate that TREM2 mediates phagocytosis via Syk signaling.

Conclusions

These results indicate that TREM2 is not associated with immunosuppression in gliomas. Instead, TREM2 is an important regulator of phagocytosis that may be exploited as a potential therapeutic strategy for brain tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicGlioblastomaMembrane GlycoproteinsPhagocytosisBrain NeoplasmsAnimalsMiceHumansTumor MicroenvironmentMyeloid CellsMice, Inbred C57BLTumor Cells, CulturedSignal Transduction

Stichwörter der Autor:innen

TREM2glioblastomamicrogliaphagocytosis

Substanzen

Receptors, ImmunologicMembrane GlycoproteinsTREM2 protein, humanTrem2 protein, mouse

Autor:innen und Institutionen

  • Department of Translational Molecular Pathology, Neurosurgery at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Translational Molecular Pathology, The University of Texas, MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Department of Genomic Medicine, Neurosurgery at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neurological Surgery, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Electrical and Computer Engineering, University of Houston, Houston, Texas, USA.
  • Departments of Translational Molecular Pathology, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.

ORCID-Profile: Antonio Iavarone, Linghua Wang, Krishna P Bhat

Förderung

  • NCI NIH HHS
  • NIH HHS
  • The University of Texas (UT) MD Anderson Cancer Center
  • NIH
  • UT MDACC
  • American Legion Auxiliary Fellowship in Cancer Research
  • UT MDACC Odyssey
  • UT MDACC Divisional Research

Zitieren

APA

Peshoff, M. M., Gupta, P., Oberai, S., Trivedi, R., Katayama, H., Chakrapani, P., Dang, M., Migliozzi, S., Gumin, J., Kadri, D. B., Lin, J. K., Milam, N. K., Maynard, M. E., Vaillant, B. D., Parker-Kerrigan, B., Lang, F. F., Huse, J. T., Iavarone, A., Wang, L., …, & Bhat, K. P. (2024). Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro-Oncology, 26(5), 826-839. https://doi.org/10.1093/neuonc/noad257

Vancouver

Peshoff MM, Gupta P, Oberai S, Trivedi R, Katayama H, Chakrapani P, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro-Oncology. 2024;26(5):826-839. doi:10.1093/neuonc/noad257

BibTeX
@article{Peshoff2024,
  author = {Peshoff, Mekenzie M and Gupta, Pravesh and Oberai, Shivangi and Trivedi, Rakesh and Katayama, Hiroshi and Chakrapani, Prashanth and Dang, Minghao and Migliozzi, Simona and Gumin, Joy and Kadri, Divya B and Lin, Jessica K and Milam, Nancy K and Maynard, Mark E and Vaillant, Brian D and Parker-Kerrigan, Brittany and Lang, Frederick F and Huse, Jason T and Iavarone, Antonio and Wang, Linghua and Clise-Dwyer, Karen and Bhat, Krishna P},
  title = {Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {5},
  pages = {826--839},
  doi = {10.1093/neuonc/noad257}
}
Kostenlos starten →